Teva Pharmaceutical Industries Ltd (Teva) (TASE:TEVA) (NYSE:TEVA), a global leader in generic medicines, announced on Friday the launch of a generic version of EXJADE (deferasirox) tablets for oral suspension, 125 mg, 250 mg and 500 mg, in the US.

EXJADE is a registered trademark of Novartis Pharmaceuticals Corporation.

Deferasirox tablets for oral suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older.

According to the company, it is offering an affordable generic treatment option with the launch of Deferasirox tablets for oral suspension in the US.

Reportedly, with nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. Currently, one in eight generic prescriptions dispensed in the US is filled with a Teva generic product.

Deferasirox tablets for oral suspension are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in patients two years of age and older.